Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Avalo Therapeutics (AVTX), a clinical stage biotechnology company specializing in immune dysregulation treatments, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Garry A. Neil, CEO and Board Chairman, will deliver a presentation at this virtual event on Tuesday, February 11, 2025, at 10:00 a.m ET.

Interested parties can access both the live webcast and replay through the 'News / Events' section of Avalo's investor relations website at ir.avalotx.com. The presentation recording will remain available for a minimum of 30 days following the event.

WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET.

Live webcast and replay can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com 
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

FAQ

When is Avalo Therapeutics (AVTX) presenting at the Oppenheimer Healthcare Conference 2025?

Avalo Therapeutics will present at the Oppenheimer Healthcare Conference on Tuesday, February 11, 2025, at 10:00 a.m ET.

How can investors watch AVTX's Oppenheimer Conference presentation?

Investors can watch the presentation live or access the replay through the 'News / Events' section of Avalo's investor relations website at ir.avalotx.com.

How long will AVTX's Oppenheimer Conference presentation replay be available?

The archived webcast will be available for replay for at least 30 days following the presentation.

Who will be presenting for AVTX at the Oppenheimer Healthcare Conference?

Dr. Garry A. Neil, Chief Executive Officer and Chairman of the Board, will be presenting for Avalo Therapeutics.

What is the focus area of Avalo Therapeutics (AVTX)?

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.